Bimekizumab-induced eczematous eruption treated successfully with sequential upadacitinib and dupilumab therapy

Bimekizumab, a selective IL-17A and IL-17F inhibitor, is FDA-approved for the treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. While IL-17 inhibitors are generally well tolerated, there have been reports of eczematous eruptions after starting treatment with this medication class. Herein, we report a case of bimekizumab-induced eczematous eruption that partially cleared with upadacitinib (selective oral JAK 1 inhibitor), but ultimately required switching to dupilumab to achieve complete skin clearance.